{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T09:20:15Z","timestamp":1780392015263,"version":"3.54.1"},"reference-count":103,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T00:00:00Z","timestamp":1773878400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T00:00:00Z","timestamp":1773878400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["AAPS PharmSciTech"],"DOI":"10.1208\/s12249-026-03392-9","type":"journal-article","created":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T23:02:15Z","timestamp":1773961335000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Innovative Nanocarriers of Sorafenib in the Optimisation of Therapeutic Outcome: Challenges and Applications in Breast Cancer"],"prefix":"10.1208","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0009-0004-6764-8597","authenticated-orcid":false,"given":"Nishtha","family":"Chaurawal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8358-5304","authenticated-orcid":false,"given":"Amalia Ruiz","family":"Estrada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0837-5208","authenticated-orcid":false,"given":"Klaus","family":"Pors","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8159-8005","authenticated-orcid":false,"given":"Kaisar","family":"Raza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3362-7558","authenticated-orcid":false,"given":"Muhammad","family":"Wahajuddin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,19]]},"reference":[{"key":"3392_CR1","unstructured":"Cancer Today [Internet]. [cited 2024 Sep 16]. Available from: https:\/\/gco.iarc.fr\/today\/en\/dataviz\/pie?mode=cancer&group_populations=1."},{"key":"3392_CR2","unstructured":"Female Breast Cancer \u2014 Cancer Stat Facts [Internet]. [cited 2025 Nov 29]. Available from: https:\/\/seer.cancer.gov\/statfacts\/html\/breast.html."},{"key":"3392_CR3","doi-asserted-by":"crossref","unstructured":"Zhang S, Jin Z, Bao L, Shu P. The global burden of breast cancer in women from 1990 to 2030: assessment and projection based on the global burden of disease study 2019. Front Oncol [Internet]. Frontiers Media SA; 2024 [cited 2025 Nov 30];14:1364397. Available from: https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC11222408\/.","DOI":"10.3389\/fonc.2024.1364397"},{"key":"3392_CR4","unstructured":"Breast Cancer Dataset [Internet]. [cited 2025 Nov 29]. Available from: https:\/\/www.kaggle.com\/datasets\/yasserh\/breast-cancer-dataset."},{"key":"3392_CR5","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1016\/j.neo.2020.09.009","volume":"22","author":"S Taurin","year":"2020","unstructured":"Taurin S, Alkhalifa H. Breast cancers, mammary stem cells, and cancer stem cells, characteristics, and hypotheses. Neoplasia. 2020;22:663\u201378. https:\/\/doi.org\/10.1016\/j.neo.2020.09.009.","journal-title":"Neoplasia"},{"key":"3392_CR6","doi-asserted-by":"crossref","unstructured":"Kerr AJ, Dodwell D, McGale P, Holt F, Duane F, Mannu G, et al. Adjuvant and neoadjuvant breast cancer treatments: A systematic review of their effects on mortality. Cancer Treat Rev [Internet]. W.B. Saunders Ltd; 2022 [cited 2025 Nov 29];105:None. Available from: https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC9096622\/.","DOI":"10.1016\/j.ctrv.2022.102375"},{"key":"3392_CR7","doi-asserted-by":"crossref","unstructured":"Lv L, Zhao B, Kang J, Li S, Wu H. Trend of disease burden and risk factors of breast cancer in developing countries and territories, from 1990 to 2019: Results from the Global Burden of Disease Study 2019. Front Public Heal [Internet]. Frontiers Media SA; 2022 [cited 2024 Sep 16];10. Available from: \/pmc\/articles\/PMC9884979\/.","DOI":"10.3389\/fpubh.2022.1078191"},{"key":"3392_CR8","doi-asserted-by":"crossref","unstructured":"Liu J, Shi X, Niu Z, Qian C. Comparative efficacy of intraoperative radiotherapy and external boost irradiation in early-stage breast cancer: a systematic review and meta-analysis. PeerJ [Internet]. PeerJ Inc.; 2023 [cited 2025 Nov 29];11:e15949. Available from: https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC10512934\/.","DOI":"10.7717\/peerj.15949"},{"key":"3392_CR9","doi-asserted-by":"crossref","unstructured":"Peng J, Madduri S, Clontz AD, Stewart DA. Clinical trial-identified inflammatory biomarkers in breast and pancreatic cancers. Front Endocrinol (Lausanne) [Internet]. Frontiers Media S.A.; 2023 [cited 2025 Nov 29];14:1106520. Available from: https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC10173309\/.","DOI":"10.3389\/fendo.2023.1106520"},{"key":"3392_CR10","doi-asserted-by":"publisher","first-page":"331","DOI":"10.5306\/wjco.v7.i4.331","volume":"7","author":"M Zafrakas","year":"2016","unstructured":"Zafrakas M, Papasozomenou P, Emmanouilides C. Sorafenib in breast cancer treatment: a systematic review and overview of clinical trials. World J Clin Oncol. 2016;7:331\u20136.","journal-title":"World J Clin Oncol"},{"key":"3392_CR11","doi-asserted-by":"crossref","unstructured":"Gomez P, Lacouture ME. Clinical Presentation and Management of Hand\u2013Foot Skin Reaction Associated with Sorafenib in Combination with Cytotoxic Chemotherapy: Experience in Breast Cancer. Oncologist [Internet]. Oxford University Press (OUP); 2011 [cited 2025 Nov 29];16:1508. Available from: https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC3233284\/.","DOI":"10.1634\/theoncologist.2011-0115"},{"key":"3392_CR12","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1097\/CAD.0b013e32832b2ea0","volume":"20","author":"G Bianchi","year":"2009","unstructured":"Bianchi G, Loibl S, Zamagni C, Salvagni S, Raab G, Siena S, et al. Phase II multicenter, uncontrolled trial of sorafenib in patients with metastatic breast cancer. Anticancer Drugs. 2009;20:616\u201324.","journal-title":"Anticancer Drugs"},{"key":"3392_CR13","doi-asserted-by":"publisher","unstructured":"Li Y, Gao ZH, Qu XJ. The Adverse Effects of Sorafenib in Patients with Advanced Cancers. Basic Clin Pharmacol Toxicol [Internet]. John Wiley & Sons, Ltd; 2015 [cited 2024 Sep 16];116:216\u201321. Available from: https:\/\/onlinelibrary.wiley.com\/doi\/full\/https:\/\/doi.org\/10.1111\/bcpt.12365.","DOI":"10.1111\/bcpt.12365"},{"key":"3392_CR14","doi-asserted-by":"crossref","unstructured":"Liu CY, Tseng LM, Su JC, Chang KC, Chu PY, Tai WT, et al. Novel sorafenib analogues induce apoptosis through SHP-1 dependent STAT3 inactivation in human breast cancer cells. Breast Cancer Res [Internet]. BioMed Central Ltd.; 2013 [cited 2025 Nov 29];15:R63. Available from: https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC3978748\/.","DOI":"10.1186\/bcr3457"},{"key":"3392_CR15","doi-asserted-by":"crossref","unstructured":"Raut H, Jadhav C, Shetty K, Laxane N, Nijhawan HP, Rao GK, et al. Sorafenib tosylate novel drug delivery systems: Implications of nanotechnology in both approved and unapproved indications. OpenNano. Elsevier; 2022;8:100103.","DOI":"10.1016\/j.onano.2022.100103"},{"key":"3392_CR16","doi-asserted-by":"crossref","unstructured":"Gong L, Zhang Y, Yang Y, Yan Q, Ren J, Luo J, et al. Inhibition of lysyl oxidase\u2010like 2 overcomes adhesion\u2010dependent drug resistance in the collagen\u2010enriched liver cancer microenvironment. Hepatol Commun [Internet]. John Wiley and Sons Inc; 2022 [cited 2025 Nov 29];6:3194. Available from: https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC9592791\/.","DOI":"10.1002\/hep4.1966"},{"key":"3392_CR17","doi-asserted-by":"crossref","unstructured":"Battaglia L, Dianzani C, Muntoni E, Marini E, Bozza A, Bordano V, et al. Ultrasmall solid lipid nanoparticles as a potential innovative delivery system for a drug combination against glioma. Nanomedicine [Internet]. Taylor and Francis Ltd.; 2024 [cited 2025 Nov 29];20:37. Available from: https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC11703491\/.","DOI":"10.1080\/17435889.2024.2434452"},{"key":"3392_CR18","doi-asserted-by":"crossref","unstructured":"Das S, Satapathy BS, Pattnaik G, Pattanaik S, Alhamhoom Y, Rahamathulla M, et al. Design and Optimization of Trastuzumab-Functionalized Nanolipid Carriers for Targeted Capecitabine Delivery: Anti-Cancer Effectiveness Evaluation in MCF-7 and SKBR3 Cells. Int J Nanomedicine [Internet]. Informa UK Limited; 2025 [cited 2025 Nov 29];20:12075. Available from: https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC12503056\/.","DOI":"10.2147\/IJN.S541332"},{"key":"3392_CR19","doi-asserted-by":"crossref","unstructured":"Mohapatra D, Senapati PC, Senapati S, Pandey V, Dubey PK, Singh S, et al. Quality-by-design-based microemulsion of disulfiram for repurposing in melanoma and breast cancer therapy. Ther Deliv [Internet]. Taylor and Francis Ltd.; 2024 [cited 2025 Nov 29];15:521. Available from: https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC11412148\/.","DOI":"10.1080\/20415990.2024.2363136"},{"key":"3392_CR20","doi-asserted-by":"crossref","unstructured":"Komura Y, Kimura S, Hirasawa Y, Katagiri T, Takaura A, Yoshida F, et al. Photodynamic Therapy Using IR-783 Liposomes for Advanced Tongue and Breast Cancers in Humans. J Funct Biomater [Internet]. Multidisciplinary Digital Publishing Institute (MDPI); 2024 [cited 2025 Nov 29];15:363. Available from: https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC11678438\/.","DOI":"10.3390\/jfb15120363"},{"key":"3392_CR21","doi-asserted-by":"crossref","unstructured":"Zafaryab M, Vig K. Biomedical Application of Nanogels: From Cancer to Wound Healing. Molecules [Internet]. Multidisciplinary Digital Publishing Institute (MDPI); 2025 [cited 2025 Nov 29];30:2144. Available from: https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC12113771\/.","DOI":"10.3390\/molecules30102144"},{"key":"3392_CR22","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-022-17333-6","author":"N Chaurawal","year":"2022","unstructured":"Chaurawal N, Misra C, Abul Barkat H, Jatyan R, Chitkara D, Barkat MA, et al. Oral sorafenib-loaded microemulsion for breast cancer: evidences from the in-vitro evaluations and pharmacokinetic studies. Sci Rep. 2022. https:\/\/doi.org\/10.1038\/s41598-022-17333-6.","journal-title":"Sci Rep"},{"key":"3392_CR23","doi-asserted-by":"crossref","unstructured":"Edis Z, Wang J, Waqas MK, Ijaz M, Ijaz M. Nanocarriers-Mediated Drug Delivery Systems for Anticancer Agents: An Overview and Perspectives. Int J Nanomedicine [Internet]. Dove Medical Press Ltd; 2021 [cited 2025 Nov 29];16:1313. Available from: https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC7898224\/.","DOI":"10.2147\/IJN.S289443"},{"key":"3392_CR24","doi-asserted-by":"crossref","unstructured":"Zhang RX, Wong HL, Xue HY, Eoh JY, Wu XY. Nanomedicine of synergistic drug combinations for cancer therapy \u2013 strategies and perspectives. J Control Release [Internet]. Elsevier B.V.; 2016 [cited 2025 Nov 29];240:489. Available from: https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC5064882\/.","DOI":"10.1016\/j.jconrel.2016.06.012"},{"key":"3392_CR25","doi-asserted-by":"crossref","unstructured":"Wang L, Chen M, Ran X, Tang H, Cao D. Sorafenib-Based Drug Delivery Systems: Applications and Perspectives. Polymers (Basel) [Internet]. Polymers (Basel); 2023 [cited 2024 Sep 16];15. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/37376284\/.","DOI":"10.3390\/polym15122638"},{"key":"3392_CR26","doi-asserted-by":"publisher","DOI":"10.3390\/bioengineering9070320","author":"R Arshad","year":"2022","unstructured":"Arshad R, Kiani MH, Rahdar A, Sargazi S, Barani M, Shojaei S, et al. Nano-based theranostic platforms for breast cancer: a review of latest advancements. Bioengineering. 2022. https:\/\/doi.org\/10.3390\/bioengineering9070320.","journal-title":"Bioengineering"},{"key":"3392_CR27","doi-asserted-by":"publisher","first-page":"10","DOI":"10.3949\/ccjm.75.Suppl_1.S10","volume":"75","author":"C Hammer","year":"2008","unstructured":"Hammer C, Fanning A, Crowe J. Overview of breast cancer staging and surgical treatment options. Cleve Clin J Med. 2008;75:10\u20136.","journal-title":"Cleve Clin J Med"},{"key":"3392_CR28","doi-asserted-by":"crossref","unstructured":"Bartkowiak-Wieczorek J, Jaros A, Gajdzi\u0144ska A, Wojty\u0142a-Buciora P, Szyma\u0144ski I, Szymaniak J, et al. The Dual Faces of Oestrogen: The Impact of Exogenous Oestrogen on the Physiological and Pathophysiological Functions of Tissues and Organs. Int J Mol Sci [Internet]. Multidisciplinary Digital Publishing Institute (MDPI); 2024 [cited 2025 Nov 29];25:8167. Available from: https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC11311417\/.","DOI":"10.3390\/ijms25158167"},{"key":"3392_CR29","doi-asserted-by":"crossref","unstructured":"Freelander A, Brown LJ, Parker A, Segara D, Portman N, Lau B, et al. Molecular Biomarkers for Contemporary Therapies in Hormone Receptor-Positive Breast Cancer. Genes (Basel) [Internet]. MDPI AG; 2021 [cited 2025 Nov 29];12:285. Available from: https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC7922594\/.","DOI":"10.3390\/genes12020285"},{"key":"3392_CR30","doi-asserted-by":"publisher","unstructured":"Tarighati E, Keivan \u00b7 Hadi, Mahani \u00b7 Hojjat. A review of prognostic and predictive biomarkers in breast cancer. 2023 [cited 2024 Apr 5];23:1\u201316. Available from: https:\/\/doi.org\/10.1007\/s10238-021-00781-1.","DOI":"10.1007\/s10238-021-00781-1"},{"key":"3392_CR31","doi-asserted-by":"publisher","unstructured":"Allison KH, Hammond MEH, Dowsett M, McKernin SE, Carey LA, Fitzgibbons PL, et al. Estrogen and progesterone receptor testing in breast cancer: ASCO\/CAP guideline update. J Clin Oncol [Internet]. American Society of Clinical Oncology; 2020 [cited 2024 Apr 5];38:1346\u201366. Available from: https:\/\/ascopubs.org\/doi\/https:\/\/doi.org\/10.1200\/JCO.19.02309.","DOI":"10.1200\/JCO.19.02309"},{"key":"3392_CR32","doi-asserted-by":"crossref","unstructured":"Li Z, Wei H, Li S, Wu P, Mao X. The Role of Progesterone Receptors in Breast Cancer. Drug Des Devel Ther [Internet]. Dove Medical Press Ltd; 2022 [cited 2025 Nov 29];16:305. Available from: https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC8801368\/.","DOI":"10.2147\/DDDT.S336643"},{"key":"3392_CR33","unstructured":"Hammond MEH, Hayes DF, Dowsett M, Allred DC, Hagerty KL, Badve S, et al. American Society of Clinical Oncology\/College of American Pathologists Guideline Recommendations for Immunohistochemical Testing of Estrogen and Progesterone Receptors in Breast Cancer. J Clin Oncol [Internet]. American Society of Clinical Oncology; 2010 [cited 2025 Nov 29];28:2784. Available from: https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC2881855\/."},{"key":"3392_CR34","doi-asserted-by":"crossref","unstructured":"Lau KH, Tan AM, Shi Y. New and Emerging Targeted Therapies for Advanced Breast Cancer. Int J Mol Sci [Internet]. MDPI; 2022 [cited 2025 Nov 29];23:2288. Available from: https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC8874375\/.","DOI":"10.3390\/ijms23042288"},{"key":"3392_CR35","doi-asserted-by":"crossref","unstructured":"Phillips JB, Park SS, Lin CH, Cho J, Lim S, Aurora R, et al. SON is an essential RNA splicing factor promoting ErbB2 and ErbB3 expression in breast cancer. Br J Cancer [Internet]. Springer Nature; 2024 [cited 2025 Nov 29];131:1437. Available from: https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC11519869\/.","DOI":"10.1038\/s41416-024-02853-x"},{"key":"3392_CR36","doi-asserted-by":"crossref","unstructured":"Siatis KE, Giannopoulou E, Manou D, Sarantis P, Karamouzis M V., Raftopoulou S, et al. Resistance to hormone therapy in breast cancer cells promotes autophagy and EGFR signaling pathway. Am J Physiol - Cell Physiol [Internet]. American Physiological Society; 2023 [cited 2025 Nov 29];325:C708. Available from: https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC10625825\/.","DOI":"10.1152\/ajpcell.00199.2023"},{"key":"3392_CR37","doi-asserted-by":"publisher","unstructured":"Wolff AC, Elizabeth Hale Hammond M, Allison KH, Harvey BE, McShane LM, Dowsett M. HER2 Testing in Breast Cancer: American Society of Clinical Oncology\/College of American Pathologists Clinical Practice Guideline Focused Update Summary. 10.1200\/JOP1800206 [Internet]. American Society of Clinical Oncology; 2018 [cited 2024 Apr 5];14:437\u201341. Available from: https:\/\/ascopubs.org\/doi\/https:\/\/doi.org\/10.1200\/JOP.18.00206.","DOI":"10.1200\/JOP.18.00206"},{"key":"3392_CR38","doi-asserted-by":"crossref","unstructured":"Heaphy CM, Subhawong AP, Gross AL, Konishi Y, Kouprina N, Argani P, et al. Shorter telomeres in luminal B, HER-2 and triple-negative breast cancer subtypes. Mod Pathol [Internet]. Nature Publishing Group; 2010 [cited 2025 Nov 29];24:194. Available from: https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC4416483\/.","DOI":"10.1038\/modpathol.2010.198"},{"key":"3392_CR39","doi-asserted-by":"publisher","first-page":"1145","DOI":"10.1056\/NEJMoa2203690","volume":"387","author":"S Modi","year":"2022","unstructured":"Modi S, Gambhire D, Cameron D, Massachusetts Medical Society. Trastuzumab deruxtecan in HER2-low breast cancer. Reply. N Engl J Med. 2022;387:1145\u20136.","journal-title":"N Engl J Med"},{"key":"3392_CR40","doi-asserted-by":"crossref","unstructured":"Lucas E, Jabbar SB, Molberg K, Fang Y, Xie XJ, Blacketer S, et al. Comparison of dako herceptest and ventana PATHWAY Anti-HER2 (4B5) tests and their correlation with fluorescent in situ hybridization in Breast Carcinoma. Appl Immunohistochem Mol Morphol [Internet]. Lippincott Williams and Wilkins; 2019 [cited 2024 Apr 5];27:403\u20139. Available from: https:\/\/journals.lww.com\/appliedimmunohist\/fulltext\/2019\/07000\/comparison_of_dako_herceptest_and_ventana_pathway.1.aspx.","DOI":"10.1097\/PAI.0000000000000646"},{"key":"3392_CR41","doi-asserted-by":"publisher","unstructured":"Krystel-Whittemore M, Hoon Tan P, Wen HY. Predictive and prognostic biomarkers in breast tumours. 2023 [cited 2024 Mar 19]; Available from: https:\/\/doi.org\/10.1016\/j.pathol.2023.10.014.","DOI":"10.1016\/j.pathol.2023.10.014"},{"key":"3392_CR42","doi-asserted-by":"crossref","unstructured":"Garc\u00eda-Saenz J\u00c1, Rodr\u00edguez-Lescure \u00c1, Cruz J, Albanell J, Alba E, Llombart A. Second-Line Treatment Options for Patients with Metastatic Triple-Negative Breast Cancer: A Review of the Clinical Evidence. Target Oncol [Internet]. Adis; 2025 [cited 2025 Nov 29];20:191. Available from: https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC11933194\/.","DOI":"10.1007\/s11523-024-01125-1"},{"key":"3392_CR43","doi-asserted-by":"crossref","unstructured":"Lebert JM, Lester R, Powell E, Seal M, McCarthy J. Advances in the systemic treatment of triple-negative breast cancer. Curr Oncol [Internet]. Multimed Inc.; 2018 [cited 2025 Nov 29];25:S142. Available from: https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC6001760\/.","DOI":"10.3747\/co.25.3954"},{"key":"3392_CR44","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1080\/14656566.2017.1309024","volume":"18","author":"G Bronte","year":"2017","unstructured":"Bronte G, Andreis D, Bravaccini S, Maltoni R, Cecconetto L, Schirone A, et al. Sorafenib for the treatment of breast cancer. Expert Opin Pharmacother. 2017;18:621\u201330. https:\/\/doi.org\/10.1080\/14656566.2017.1309024.","journal-title":"Expert Opin Pharmacother"},{"key":"3392_CR45","doi-asserted-by":"crossref","unstructured":"Tan Q-X, Qin Q-H, Lian B, Yang W-P, Wei C-Y. Sorafenib-based therapy in HER2-negative advanced breast cancer: results from a retrospective pooled analysis of randomized controlled trials. Exp Ther Med [Internet]. Centre for Reviews and Dissemination (UK); 2014 [cited 2024 May 26];7:1420\u20136. Available from: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK290829\/.","DOI":"10.3892\/etm.2014.1603"},{"key":"3392_CR46","doi-asserted-by":"crossref","unstructured":"Regen-Tuero HC, Ward RC, Sikov WM, Littrup PJ. Cryoablation and Immunotherapy for Breast Cancer: Overview and Rationale for Combined Therapy. Radiol Imaging Cancer [Internet]. Radiological Society of North America Inc.; 2021 [cited 2025 Nov 29];3:e200134. Available from: https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC8011444\/.","DOI":"10.1148\/rycan.2021200134"},{"key":"3392_CR47","doi-asserted-by":"crossref","unstructured":"Montero AJ, Escobar M, Lopes G, Gl\u00fcck S, Vogel C. Bevacizumab in the Treatment of Metastatic Breast Cancer: Friend or Foe? Curr Oncol Rep [Internet]. Current Medicine Group LLC 1; 2012 [cited 2025 Nov 29];14:1. Available from: https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC3266439\/.","DOI":"10.1007\/s11912-011-0202-z"},{"key":"3392_CR48","doi-asserted-by":"crossref","unstructured":"Staton C, Yang Z, Reed M, Brown N. Bevacizumab resistance in breast cancer: are neuropilins the key? Breast Cancer Res [Internet]. Springer Nature; 2008 [cited 2025 Nov 29];10:P75. Available from: https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC3300778\/.","DOI":"10.1186\/bcr1959"},{"key":"3392_CR49","doi-asserted-by":"publisher","first-page":"655","DOI":"10.2217\/fon.10.41","volume":"6","author":"A Moreno-Aspitia","year":"2010","unstructured":"Moreno-Aspitia A. Clinical overview of sorafenib in breast cancer. Future Oncol. 2010;6:655\u201363.","journal-title":"Future Oncol"},{"key":"3392_CR50","doi-asserted-by":"crossref","unstructured":"Yang SX. Bevacizumab and breast cancer: current therapeutic progress and future perspectives. Expert Rev Anticancer Ther [Internet]. 2009 [cited 2025 Nov 29];9:1715. Available from: https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC2819039\/.","DOI":"10.1586\/era.09.153"},{"key":"3392_CR51","doi-asserted-by":"crossref","unstructured":"Hu X, Cao J, Hu W, Wu C, Pan Y, Cai L, et al. Multicenter phase II study of Apatinib in non-triple-negative metastatic breast cancer. BMC Cancer [Internet]. BMC; 2014 [cited 2024 May 26];14. Available from: \/pmc\/articles\/PMC4237755\/.","DOI":"10.1186\/1471-2407-14-820"},{"key":"3392_CR52","doi-asserted-by":"crossref","unstructured":"Miles D, Cameron D, Bondarenko I, Manzyuk L, Alcedo JC, Lopez RI, et al. Bevacizumab plus paclitaxel versus placebo plus paclitaxel as first-line therapy for HER2-negative metastatic breast cancer (MERiDiAN): A double-blind placebo-controlled randomised phase III trial with prospective biomarker evaluation. Eur J Cancer [Internet]. Eur J Cancer; 2017 [cited 2024 Sep 17];70:146\u201355. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/27817944\/.","DOI":"10.1016\/j.ejca.2016.09.024"},{"key":"3392_CR53","doi-asserted-by":"crossref","unstructured":"Ang YLE, Ho GF, Soo RA, Sundar R, Tan SH, Yong WP, et al. A randomized phase II trial evaluating the addition of low dose, short course sunitinib to docetaxel in advanced solid tumours. BMC Cancer [Internet]. BioMed Central Ltd; 2020 [cited 2026 Jan 12];20:1118. Available from: https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC7672922\/.","DOI":"10.1186\/s12885-020-07616-4"},{"key":"3392_CR54","doi-asserted-by":"crossref","unstructured":"Sweeney CJ, Chiorean EG, Verschraegen CF, Lee FC, Jones S, Royce M, et al. A Phase I Study of Sunitinib Plus Capecitabine in Patients With Advanced Solid Tumors. J Clin Oncol [Internet]. 2010 [cited 2026 Jan 12];28:4513. Available from: https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC2988641\/.","DOI":"10.1200\/JCO.2009.26.9696"},{"key":"3392_CR55","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1093\/jjco\/hyz213","volume":"50","author":"T Shien","year":"2020","unstructured":"Shien T, Iwata H. Adjuvant and neoadjuvant therapy for breast cancer. Jpn J Clin Oncol. 2020;50:225\u20139.","journal-title":"Jpn J Clin Oncol"},{"key":"3392_CR56","doi-asserted-by":"crossref","unstructured":"Gong L, Giacomini MM, Giacomini C, Maitland ML, Altman RB, Klein TE. PharmGKB summary: Sorafenib pathways. Pharmacogenet Genomics [Internet]. Lippincott Williams and Wilkins; 2017 [cited 2025 Nov 30];27:240\u20136. Available from: https:\/\/blog.clinpgx.org\/sorafenib-pathways-published-in\/.","DOI":"10.1097\/FPC.0000000000000279"},{"key":"3392_CR57","doi-asserted-by":"crossref","unstructured":"Lang L. FDA Approves Sorafenib for Patients With Inoperable Liver Cancer. Gastroenterology [Internet]. Elsevier; 2008 [cited 2021 Oct 19];134:379. Available from: http:\/\/www.gastrojournal.org\/article\/S0016508507022755\/fulltext.","DOI":"10.1053\/j.gastro.2007.12.037"},{"key":"3392_CR58","doi-asserted-by":"crossref","unstructured":"Kane RC, Farrell AT, Saber H, Tang S, Williams G, Jee JM, et al. Sorafenib for the treatment of advanced renal cell carcinoma. Clin Cancer Res [Internet]. Clin Cancer Res; 2006 [cited 2025 Nov 30];12:7271\u20138. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/17189398\/.","DOI":"10.1158\/1078-0432.CCR-06-1249"},{"key":"3392_CR59","doi-asserted-by":"publisher","unstructured":"von Minckwitz G, Huang C-S, Mano MS, Loibl S, Mamounas EP, Untch M, et al. Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer. N Engl J Med [Internet]. Massachusetts Medical Society; 2019 [cited 2025 Nov 29];380:617\u201328. Available from: https:\/\/www.nejm.org\/doi\/pdf\/https:\/\/doi.org\/10.1056\/NEJMoa1814017.","DOI":"10.1056\/NEJMoa1814017"},{"key":"3392_CR60","doi-asserted-by":"publisher","unstructured":"Bardia A, Hurvitz SA, Tolaney SM, Loirat D, Punie K, Oliveira M, et al. Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer. N Engl J Med [Internet]. Massachusetts Medical Society; 2021 [cited 2025 Nov 29];384:1529\u201341. Available from: https:\/\/www.nejm.org\/doi\/pdf\/https:\/\/doi.org\/10.1056\/NEJMoa2028485.","DOI":"10.1056\/NEJMoa2028485"},{"key":"3392_CR61","unstructured":"Fam-Trastuzumab Deruxtecan-nxki - NCI [Internet]. [cited 2025 Nov 29]. Available from: https:\/\/www.cancer.gov\/about-cancer\/treatment\/drugs\/famtrastuzumabderuxtecan-nxki."},{"key":"3392_CR62","doi-asserted-by":"crossref","unstructured":"McCrea C, Hettle R, Gulati P, Taneja A, Rajora P. Indirect treatment comparison of olaparib and talazoparib in germline BRCA-mutated HER2-negative metastatic breast cancer. J Comp Eff Res [Internet]. J Comp Eff Res; 2021 [cited 2025 Nov 29];10:1021\u201330. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/34231369\/.","DOI":"10.2217\/cer-2021-0097"},{"key":"3392_CR63","doi-asserted-by":"crossref","unstructured":"Cejuela M, Gil-Torralvo A, Castilla M\u00c1, Dom\u00ednguez-Cejudo M\u00c1, Falc\u00f3n A, Benavent M, et al. Abemaciclib, Palbociclib, and Ribociclib in Real-World Data: A Direct Comparison of First-Line Treatment for Endocrine-Receptor-Positive Metastatic Breast Cancer. Int J Mol Sci [Internet]. Multidisciplinary Digital Publishing Institute (MDPI); 2023 [cited 2025 Nov 29];24:8488. Available from: https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC10217927\/.","DOI":"10.3390\/ijms24108488"},{"key":"3392_CR64","doi-asserted-by":"publisher","unstructured":"Murthy RK, Loi S, Okines A, Paplomata E, Hamilton E, Hurvitz SA, et al. Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer. N Engl J Med [Internet]. Massachusetts Medical Society; 2020 [cited 2025 Nov 29];382:597\u2013609. Available from: https:\/\/www.nejm.org\/doi\/pdf\/https:\/\/doi.org\/10.1056\/NEJMoa1914609.","DOI":"10.1056\/NEJMoa1914609"},{"key":"3392_CR65","doi-asserted-by":"publisher","unstructured":"Andr\u00e9 F, Ciruelos E, Rubovszky G, Campone M, Loibl S, Rugo HS, et al. Alpelisib for PIK3CA -Mutated, Hormone Receptor\u2013Positive Advanced Breast Cancer . N Engl J Med [Internet]. Massachusetts Medical Society; 2019 [cited 2025 Nov 29];380:1929\u201340. Available from: https:\/\/www.nejm.org\/doi\/pdf\/https:\/\/doi.org\/10.1056\/NEJMoa1813904.","DOI":"10.1056\/NEJMoa1813904"},{"key":"3392_CR66","doi-asserted-by":"publisher","unstructured":"Schmid P, Adams S, Rugo HS, Schneeweiss A, Barrios CH, Iwata H, et al. Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer. N Engl J Med [Internet]. Massachusetts Medical Society; 2018 [cited 2025 Nov 29];379:2108\u201321. Available from: https:\/\/www.nejm.org\/doi\/pdf\/https:\/\/doi.org\/10.1056\/NEJMoa1809615.","DOI":"10.1056\/NEJMoa1809615"},{"key":"#cr-split#-3392_CR67.1","doi-asserted-by":"crossref","unstructured":"Hendrixson M, Gladkiy Y, Thyagarajan A, Sahu RP. Efficacy of Sorafenib-Based Therapies for Non-Small Cell Lung Cancer. Med Sci 2024, Vol 12, Page 20 [Internet]. Multidisciplinary Digital Publishing Institute","DOI":"10.3390\/medsci12020020"},{"key":"#cr-split#-3392_CR67.2","unstructured":"2024 [cited 2025 Nov 30];12:20. Available from: https:\/\/www.mdpi.com\/2076-3271\/12\/2\/20\/htm."},{"key":"3392_CR68","doi-asserted-by":"crossref","unstructured":"Yardley DA, Dickson N, Drosick D, Earwood C, Inhorn R, Murphy P, et al. Sorafenib Plus Ixabepilone as First-Line Treatment of Metastatic HER2-Negative Breast Cancer: A Sarah Cannon Research Institute Phase I\/II Trial. Clin Breast Cancer [Internet]. Clin Breast Cancer; 2016 [cited 2024 Jun 11];16:180\u20137. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/26943991\/.","DOI":"10.1016\/j.clbc.2016.02.003"},{"key":"3392_CR69","doi-asserted-by":"crossref","unstructured":"Wilhelm SM, Carter C, Tang LY, Wilkie D, McNabola A, Rong H, et al. BAY 43\u20139006 Exhibits Broad Spectrum Oral Antitumor Activity and Targets the RAF\/MEK\/ERK Pathway and Receptor Tyrosine Kinases Involved in Tumor Progression and Angiogenesis. Cancer Res [Internet]. American Association for Cancer Research; 2004 [cited 2024 Jun 11];64:7099\u2013109. Available from: \/cancerres\/article\/64\/19\/7099\/511824\/BAY-43\u20139006-Exhibits-Broad-Spectrum-Oral-Antitumor","DOI":"10.1158\/0008-5472.CAN-04-1443"},{"key":"3392_CR70","doi-asserted-by":"crossref","unstructured":"Loibl S, Rokitta D, Conrad B, Harbeck N, W\u00fcllner M, Warm M, et al. Sorafenib in the Treatment of Early Breast Cancer: Results of the Neoadjuvant Phase II Study - SOFIA. Breast Care (Basel) [Internet]. Breast Care (Basel); 2014 [cited 2024 Jun 11];9:169\u201374. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/25177258\/.","DOI":"10.1159\/000363430"},{"key":"3392_CR71","doi-asserted-by":"crossref","unstructured":"Yu C, Bruzek LM, Xue WM, Gores GJ, Carter CA, Kaufmann SH, et al. The role of Mcl-1 downregulation in the proapoptotic activity of the multikinase inhibitor BAY 43\u20139006. Oncogene [Internet]. Oncogene; 2005 [cited 2024 Jun 11];24:6861\u20139. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/16007148\/.","DOI":"10.1038\/sj.onc.1208841"},{"key":"3392_CR72","doi-asserted-by":"publisher","DOI":"10.1053\/j.seminoncol.2014.01.002","author":"CM Walko","year":"2014","unstructured":"Walko CM, Grande C. Management of common adverse events in patients treated with Sorafenib: nurse and pharmacist perspective. Semin Oncol. 2014. https:\/\/doi.org\/10.1053\/j.seminoncol.2014.01.002.","journal-title":"Semin Oncol"},{"key":"3392_CR73","first-page":"1","volume":"16","author":"Z Wang","year":"2025","unstructured":"Wang Z, Peng H, Zhang Y, Chen X, Jiye A. Bioequivalence and safety assessment of sorafenib tosylate tablets in healthy Chinese subjects under fasting conditions. Front Pharmacol. 2025;16:1\u20139.","journal-title":"Front Pharmacol"},{"key":"3392_CR74","doi-asserted-by":"crossref","unstructured":"Jain L, Woo S, Gardner ER, Dahut WL, Kohn EC, Kummar S, et al. Population pharmacokinetic analysis of sorafenib in patients with solid tumours. Br J Clin Pharmacol [Internet]. Br J Clin Pharmacol; 2011 [cited 2024 Sep 17];72:294\u2013305. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/21392074\/.","DOI":"10.1111\/j.1365-2125.2011.03963.x"},{"key":"3392_CR75","doi-asserted-by":"crossref","unstructured":"Zanotto-Filho A, Rajamanickam S, Loranc E, Masamsetti VP, Gorthi A, Romero JC, et al. Sorafenib improves alkylating therapy by blocking induced inflammation, invasion and angiogenesis in breast cancer cells. Cancer Lett [Internet]. Elsevier Ireland Ltd; 2018 [cited 2025 Nov 29];425:101. Available from: https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC5930000\/.","DOI":"10.1016\/j.canlet.2018.03.037"},{"key":"3392_CR76","doi-asserted-by":"crossref","unstructured":"Chan KM, Wu TH, Cheng CH, Lee CF, Wu TJ, Chou HS, et al. Implementation of sorafenib treatment for advanced hepatocellular carcinoma: an illustration of current practice in Taiwan. Cancer Manag Res [Internet]. Dove Press; 2019 [cited 2025 Nov 29];11:1013\u201321. Available from: https:\/\/www.dovepress.com\/implementation-of-sorafenib-treatment-for-advanced-hepatocellular-carc-peer-reviewed-fulltext-article-CMAR.","DOI":"10.2147\/CMAR.S186678"},{"key":"3392_CR77","doi-asserted-by":"crossref","unstructured":"Li M, Su Y, Zhang F, Chen K, Xu X, Xu L, et al. A dual-targeting reconstituted high density lipoprotein leveraging the synergy of sorafenib and antimiRNA21 for enhanced hepatocellular carcinoma therapy. Acta Biomater. 2018;75:413\u201326.","DOI":"10.1016\/j.actbio.2018.05.049"},{"key":"3392_CR78","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1016\/j.ajps.2020.07.003","volume":"16","author":"F Chen","year":"2021","unstructured":"Chen F, Fang Y, Chen X, Deng R, Zhang Y, Shao J, et al. Recent advances of sorafenib nanoformulations for cancer therapy: smart nanosystem and combination therapy. Asian J Pharm Sci. 2021;16:318\u201336. https:\/\/doi.org\/10.1016\/j.ajps.2020.07.003.","journal-title":"Asian J Pharm Sci"},{"key":"3392_CR79","doi-asserted-by":"publisher","unstructured":"Iyer R, Fetterly G, Lugade A, Thanavala Y. Sorafenib: A clinical and pharmacologic review. Expert Opin Pharmacother [Internet]. Informa Healthcare; 2010 [cited 2025 Nov 29];11:1943\u201355. Available from: https:\/\/www.tandfonline.com\/doi\/abs\/https:\/\/doi.org\/10.1517\/14656566.2010.496453.","DOI":"10.1517\/14656566.2010.496453"},{"key":"3392_CR80","doi-asserted-by":"publisher","unstructured":"Awada A, Gil T, Whenham N, Van Hamme J, Besse-Hammer T, Brendel E, et al. Safety and Pharmacokinetics of Sorafenib Combined With Capecitabine in Patients With Advanced Solid Tumors: Results of a Phase 1 Trial. J Clin Pharmacol [Internet]. John Wiley & Sons, Ltd; 2011 [cited 2024 Jun 11];51:1674\u201384. Available from: https:\/\/onlinelibrary.wiley.com\/doi\/full\/https:\/\/doi.org\/10.1177\/0091270010386226.","DOI":"10.1177\/0091270010386226"},{"key":"3392_CR81","doi-asserted-by":"publisher","unstructured":"Reiss KA, Yu S, Mamtani R, Mehta R, D\u2019Addeo K, Wileyto EP, et al. Starting dose of sorafenib for the treatment of hepatocellular carcinoma: A retrospective, multi-institutional study. J Clin Oncol [Internet]. American Society of Clinical Oncology; 2017 [cited 2025 Nov 29];35:3575\u201381. Available from: https:\/\/ascopubs.org\/doi\/pdf\/https:\/\/doi.org\/10.1200\/JCO.2017.73.8245.","DOI":"10.1200\/JCO.2017.73.8245"},{"key":"3392_CR82","doi-asserted-by":"publisher","unstructured":"Bonelli MA, Fumarola C, Alfieri RR, La Monica S, Cavazzoni A, Galetti M, et al. Synergistic activity of letrozole and sorafenib on breast cancer cells. Breast Cancer Res Treat [Internet]. Springer; 2010 [cited 2024 Jun 11];124:79\u201388. Available from: https:\/\/link.springer.com\/article\/https:\/\/doi.org\/10.1007\/s10549-009-0714-5.","DOI":"10.1007\/s10549-009-0714-5"},{"key":"3392_CR83","doi-asserted-by":"crossref","unstructured":"Ding Q, Huo L, Yang J-Y, Xia W, Wei Y, Liao Y, et al. Down-regulation of Myeloid Cell Leukemia-1 through Inhibiting Erk\/Pin 1 Pathway by Sorafenib Facilitates Chemosensitization in Breast Cancer. Cancer Res [Internet]. 2008 [cited 2024 Jun 11];68:6109\u201317. Available from: http:\/\/cancerres.aacrjournals.org\/.","DOI":"10.1158\/0008-5472.CAN-08-0579"},{"key":"3392_CR84","doi-asserted-by":"crossref","unstructured":"Isaacs C, Herbolsheimer P, Liu MC, Wilkinson M, Ottaviano Y, Chung GG, et al. Phase I\/II Study of Sorafenib with Anastrozole in Patients with Hormone Receptor Positive Aromatase Inhibitor Resistant Metastatic Breast Cancer. Breast Cancer Res Treat [Internet]. NIH Public Access; 2011 [cited 2024 Jun 11];125:137. Available from: \/pmc\/articles\/PMC3756315\/.","DOI":"10.1007\/s10549-010-1226-z"},{"key":"3392_CR85","doi-asserted-by":"publisher","first-page":"1177","DOI":"10.1517\/13543784.2012.689824","volume":"21","author":"WJ Gradishar","year":"2012","unstructured":"Gradishar WJ. Sorafenib in locally advanced or metastatic breast cancer. Expert Opin Investig Drugs. 2012;21:1177\u201391.","journal-title":"Expert Opin Investig Drugs"},{"key":"3392_CR86","doi-asserted-by":"crossref","unstructured":"Shahbazi MA, Almeida PV, Correia A, Herranz-Blanco B, Shrestha N, M\u00e4kil\u00e4 E, et al. Intracellular responsive dual delivery by endosomolytic polyplexes carrying DNA anchored porous silicon nanoparticles. J Control Release [Internet]. J Control Release; 2017 [cited 2024 Jun 13];249:111\u201322. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/28159519\/.","DOI":"10.1016\/j.jconrel.2017.01.046"},{"key":"3392_CR87","doi-asserted-by":"publisher","first-page":"2426","DOI":"10.1016\/j.xphs.2019.11.013","volume":"109","author":"J Fu","year":"2020","unstructured":"Fu J, Li W, Xin X, Chen D, Hu H, Elsevier. Transferrin-modified nanoliposome codelivery strategies for enhancing the cancer therapy. J Pharm Sci. 2020;109:2426\u201336.","journal-title":"J Pharm Sci"},{"key":"3392_CR88","doi-asserted-by":"crossref","unstructured":"Chen F, Fang Y, Chen X, Deng R, Zhang Y, Shao J. Recent advances of sorafenib nanoformulations for cancer therapy: Smart nanosystem and combination therapy. Asian J Pharm Sci [Internet]. Shenyang Pharmaceutical University; 2021 [cited 2024 Sep 17];16:318. Available from: \/pmc\/articles\/PMC8261086\/","DOI":"10.1016\/j.ajps.2020.07.003"},{"key":"3392_CR89","unstructured":"Khan MA, Raza A, Ovais M, Sohail MF, Ali S. Current state and prospects of nano-delivery systems for sorafenib. Int J Polym Mater Polym Biomater [Internet]. Taylor and Francis Inc.; 2018 [cited 2025 Nov 29];67:1105\u201315. Available from: https:\/\/scholar.google.com\/scholar_url?url=https:\/\/www.tandfonline.com\/doi\/pdf\/https:\/\/doi.org\/10.1080\/00914037.2018.1429434%3Fcasa_token%3DcxY6bXB4F6cAAAAA:2UO2jMK_Cv1-l4Z6egQRD0O0Dvp-AOvi1R6m5HFIA0ieEVPYBVkTgVoWYcoRcL_y4KwKsJ4ts7yWPQ&hl=en&sa=T&oi=ucasa&ct=ucasa&ei=kQ4raY-mM82j6rQPsvXUgA0&scisig=ABGrvjI2G05QieRwrt0YyAntff-v."},{"key":"3392_CR90","doi-asserted-by":"crossref","unstructured":"Terracciano M, Shahbazi MA, Correia A, Rea I, Lamberti A, De Stefano L, et al. Surface bioengineering of diatomite based nanovectors for efficient intracellular uptake and drug delivery. Nanoscale. 2015;7:20063\u201374.","DOI":"10.1039\/C5NR05173H"},{"key":"3392_CR91","doi-asserted-by":"crossref","unstructured":"Correia A, Shahbazi M, M\u00e4kil\u00e4 EM, Salonen JJ, Hirvonen JT, Santos HA. Cyclodextrin-Modified Porous Silicon Nanoparticles for Efficient Sustained Drug Delivery and Proliferation Inhibition of Breast Cancer Cells Cyclodextrin-Modified Porous Silicon Nanoparticles for Efficient Sustained Drug Delivery and Proliferation Inhibit. 2015;","DOI":"10.1021\/acsami.5b07033"},{"key":"3392_CR92","doi-asserted-by":"publisher","unstructured":"Mo L, Song JG, Lee H, Zhao M, Kim HY, Lee YJ, et al. PEGylated hyaluronic acid-coated liposome for enhanced in vivo efficacy of sorafenib via active tumor cell targeting and prolonged systemic exposure. Nanomedicine Nanotechnol Biol Med. 2018;14:557\u201367. https:\/\/doi.org\/10.1016\/j.nano.2017.12.003.","DOI":"10.1016\/j.nano.2017.12.003"},{"key":"3392_CR93","doi-asserted-by":"publisher","first-page":"6209","DOI":"10.7150\/thno.36283","volume":"9","author":"M Sang","year":"2019","unstructured":"Sang M, Luo R, Bai Y, Dou J, Zhang Z, Liu F, et al. Mitochondrial membrane anchored photosensitive nano-device for lipid hydroperoxides burst and inducing ferroptosis to surmount therapy-resistant cancer. Theranostics. 2019;9:6209\u201323.","journal-title":"Theranostics"},{"key":"3392_CR94","doi-asserted-by":"publisher","first-page":"2426","DOI":"10.1016\/j.xphs.2019.11.013","volume":"109","author":"J Fu","year":"2020","unstructured":"Fu J, Li W, Xin X, Chen D, Hu H, Elsevier Ltd. Transferrin-modified nanoliposome codelivery strategies for enhancing the cancer therapy. J Pharm Sci. 2020;109:2426\u201336. https:\/\/doi.org\/10.1016\/j.xphs.2019.11.013.","journal-title":"J Pharm Sci"},{"key":"3392_CR95","doi-asserted-by":"publisher","unstructured":"Tahir N, Madni A, Li W, Correia A, Muzamil M, Abdur M, et al. Microfluidic fabrication and characterization of Sorafenib-loaded lipid- polymer hybrid nanoparticles for controlled drug delivery. Int J Pharm [Internet]. Elsevier; 2020;581:119275. Available from: https:\/\/doi.org\/10.1016\/j.ijpharm.2020.119275.","DOI":"10.1016\/j.ijpharm.2020.119275"},{"key":"3392_CR96","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/adhm.202100683","volume":"10","author":"T Zuo","year":"2021","unstructured":"Zuo T, Fang T, Zhang J, Yang J, Xu R, Wang Z, et al. pH-sensitive molecular-switch-containing polymer nanoparticle for breast cancer therapy with ferritinophagy-cascade ferroptosis and tumor immune activation. Adv Healthc Mater. 2021;10:1\u201315.","journal-title":"Adv Healthc Mater"},{"key":"3392_CR97","doi-asserted-by":"publisher","unstructured":"Huang L, Zhang Y, Li Y, Meng F, Li H, Zhang H, et al. Time-programmed delivery of sorafenib and anti-CD47 antibody via a double-layer-gel matrix for postsurgical treatment of breast cancer. Nano-Micro Lett. 2021;13:1\u201315. https:\/\/doi.org\/10.1007\/s40820-021-00647-x.","DOI":"10.1007\/s40820-021-00647-x"},{"key":"3392_CR98","doi-asserted-by":"publisher","unstructured":"Wang Z, Liu B, Tu J, Xiang J, Xiong H, Wu Y, et al. PLGA nanoparticles loaded with sorafenib combined with thermosensitive hydrogel system and microwave hyperthermia for multiple sensitized radiotherapy. Pharmaceutics. 2023. https:\/\/doi.org\/10.3390\/pharmaceutics15020487.","DOI":"10.3390\/pharmaceutics15020487"},{"key":"3392_CR99","doi-asserted-by":"publisher","unstructured":"Khafaga DSR, Eid MM, Mohamed MH, Abdelmaksoud MDE, Afify M, El-Khawaga AM, et al. Enhanced anticancer activity of silver doped zinc oxide magnetic nanocarrier loaded with sorafenib for hepatocellular carcinoma treatment. Sci Rep. 2024(1). https:\/\/doi.org\/10.1038\/s41598-024-65235-6.","DOI":"10.1038\/s41598-024-65235-6"},{"key":"3392_CR100","doi-asserted-by":"publisher","first-page":"20063","DOI":"10.1039\/C5NR05173H","volume":"7","author":"M Terracciano","year":"2015","unstructured":"Terracciano M, Shahbazi M-A, Correia A, Rea I, Lamberti A, De Stefano L, et al. Surface bioengineering of diatomite based nanovectors for efficient intracellular uptake and drug delivery. Nanoscale. 2015;7:20063\u201374.","journal-title":"Nanoscale"},{"key":"3392_CR101","doi-asserted-by":"publisher","first-page":"1401","DOI":"10.2217\/nnm-2017-0034","volume":"12","author":"PV Almeida","year":"2017","unstructured":"Almeida PV, Shahbazi MA, Correia A, M\u00e4kil\u00e4 E, Kemell M, Salonen J, et al. A multifunctional nanocomplex for enhanced cell uptake, endosomal escape and improved cancer therapeutic effect. Nanomedicine. 2017;12:1401\u201320.","journal-title":"Nanomedicine"},{"key":"3392_CR102","doi-asserted-by":"crossref","unstructured":"Benizri S, Ferey L, Alies B, Mebarek N, Vacher G, Appavoo A, et al. Nucleoside-Lipid-Based Nanocarriers for Sorafenib Delivery. Nanoscale Res Lett. Nanoscale Research Letters; 2018;13.","DOI":"10.1186\/s11671-017-2420-2"}],"container-title":["AAPS PharmSciTech"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1208\/s12249-026-03392-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1208\/s12249-026-03392-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1208\/s12249-026-03392-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T08:53:08Z","timestamp":1780390388000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1208\/s12249-026-03392-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,19]]},"references-count":103,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2026,4]]}},"alternative-id":["3392"],"URL":"https:\/\/doi.org\/10.1208\/s12249-026-03392-9","relation":{},"ISSN":["1530-9932"],"issn-type":[{"value":"1530-9932","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,19]]},"assertion":[{"value":"2 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interest"}}],"article-number":"152"}}